Abstract
Atherosclerosis is a leading cause of morbidity and mortality worldwide. Statins are established as first choice drugs for the management of hyperlipidaemia and cardiovascular risk. However, a residual cardiovascular risk, partially attributable to lipids, remains even after statin treatment. This risk appears to be associated with both high-density lipoprotein cholesterol and triglyceride lipid fractions. Several novel therapeutic approaches have been proposed to reduce lipid levels. Microsomal transfer protein (MTP) is involved in the assembly of very-low-density lipoprotein and chylomicron lipoprotein particles in the liver and the gut, respectively. In the preclinical setting, various agents that affect activity of MTP have shown that inhibition can result in profound reductions in blood triglycerides and cholesterol. Similarly, evidence of efficacy using the target has been confirmed in man with small molecule inhibitors and antisense oligonucleotides. Unfortunately, despite their efficacy in reducing lipids, the clinical utility of small molecule inhibitors has been restricted by their potential to induce hepatic steatosis. Continuing attempts to utilise this clinical target (to decrease cholesterol, triglycerides and weight) have involved the use of lower doses or non-systemically absorbed MTP inhibitors.
Keywords: Microsomal transfer protein, hepatic steatosis, drug development, triglyceride, cholesterol, cardiovascular risk
Current Vascular Pharmacology
Title: Future Challenges for Microsomal Transport Protein Inhibitors
Volume: 7 Issue: 3
Author(s): Anthony S. Wierzbicki, Tim Hardman and William T. Prince
Affiliation:
Keywords: Microsomal transfer protein, hepatic steatosis, drug development, triglyceride, cholesterol, cardiovascular risk
Abstract: Atherosclerosis is a leading cause of morbidity and mortality worldwide. Statins are established as first choice drugs for the management of hyperlipidaemia and cardiovascular risk. However, a residual cardiovascular risk, partially attributable to lipids, remains even after statin treatment. This risk appears to be associated with both high-density lipoprotein cholesterol and triglyceride lipid fractions. Several novel therapeutic approaches have been proposed to reduce lipid levels. Microsomal transfer protein (MTP) is involved in the assembly of very-low-density lipoprotein and chylomicron lipoprotein particles in the liver and the gut, respectively. In the preclinical setting, various agents that affect activity of MTP have shown that inhibition can result in profound reductions in blood triglycerides and cholesterol. Similarly, evidence of efficacy using the target has been confirmed in man with small molecule inhibitors and antisense oligonucleotides. Unfortunately, despite their efficacy in reducing lipids, the clinical utility of small molecule inhibitors has been restricted by their potential to induce hepatic steatosis. Continuing attempts to utilise this clinical target (to decrease cholesterol, triglycerides and weight) have involved the use of lower doses or non-systemically absorbed MTP inhibitors.
Export Options
About this article
Cite this article as:
Wierzbicki S. Anthony, Hardman Tim and Prince T. William, Future Challenges for Microsomal Transport Protein Inhibitors, Current Vascular Pharmacology 2009; 7 (3) . https://dx.doi.org/10.2174/157016109788340703
DOI https://dx.doi.org/10.2174/157016109788340703 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
4q21.2q21.3 Duplication: Molecular and Neuropsychological Aspects
Current Genomics Editorial (Thematic Issue: Novel Insights into the Role of Anesthetics and Opioids in Organ or Tissue Protection)
Current Pharmaceutical Design The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives
Current Topics in Medicinal Chemistry Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure
Current Pharmaceutical Design Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double –Edged Sword!
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Lipotoxicity, ER Stress, and Cardiovascular Disease: Current Understanding and Future Directions
Cardiovascular & Hematological Agents in Medicinal Chemistry Boswellic Acids: A Critical Appraisal of Their Therapeutic and Nutritional Benefits in Chronic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Rational Design and Evaluation of the Recombinant Multiepitope Protein for Serodiagnosis of Rubella
Current Pharmaceutical Biotechnology EDITORIAL (Hot Topic: Renal Sympathetic Denervation and Cardiovascular Disease: Past, Present and Future)
Current Clinical Pharmacology Extracellular Matrix Remodeling in Hypertension
Current Hypertension Reviews An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Advanced Microfluidic Vascularized Tissues as Platform for the Study of Human Diseases and Drug Development
Current Neuropharmacology ACP5: Its Structure, Distribution, Regulation and Novel Functions
Anti-Cancer Agents in Medicinal Chemistry